Immunome Inc [NASDAQ: IMNM] stock went on an upward path that rose over 2.43% on Thursday, amounting to a one-week price increase of more than 0.57%.
Over the last 12 months, IMNM stock dropped by -16.76%. The one-year Immunome Inc stock forecast points to a potential upside of 63.92. The average equity rating for IMNM stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $769.19 million, with 86.96 million shares outstanding and 76.80 million shares in the current float. Compared to the average trading volume of 1.06M shares, IMNM stock reached a trading volume of 441626 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Immunome Inc [IMNM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMNM shares is $24.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMNM stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Lake Street have made an estimate for Immunome Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 02, 2025. While these analysts kept the previous recommendation, Stephens raised their target price to Overweight. The new note on the price target was released on November 08, 2024, representing the official price target for Immunome Inc stock. Previously, the target price had yet another raise to $27, while Piper Sandler analysts kept a Overweight rating on IMNM stock.
The Price to Book ratio for the last quarter was 2.50, with the Price to Cash per share for the same quarter was set at 3.65.
IMNM Stock Performance Analysis:
Immunome Inc [IMNM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.57. With this latest performance, IMNM shares dropped by -4.54% in over the last four-week period, additionally sinking by -14.01% over the last 6 months – not to mention a drop of -16.76% in the past year of trading.
Insight into Immunome Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Immunome Inc [IMNM] shares currently have an operating margin of -1682.75% and a Gross Margin at 76.55%. Immunome Inc’s Net Margin is presently recorded at -1875.21%.
Return on Equity for this stock declined to -61.93%, with Return on Assets sitting at -61.93%.
IMNM Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMNM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Immunome Inc go to 24.72%.
Immunome Inc [IMNM] Institutonal Ownership Details
There are presently around $83.28%, or 94.07% of IMNM stock, in the hands of institutional investors. The top three institutional holders of IMNM stocks are: REDMILE GROUP, LLC with ownership of 4.89 million shares, which is approximately 8.1579%. FMR LLC, holding 4.21 million shares of the stock with an approximate value of $$50.95 million in IMNM stocks shares; and FMR LLC, currently with $$46.94 million in IMNM stock with ownership which is approximately 6.4725%.
